Clene to Participate in the Maxim Group Virtual Healthcare Conference
Get Alerts CLNN Hot Sheet
Join SI Premium – FREE
SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that Rob Etherington, Chief Executive Officer, will participate in a fireside chat with Naz Rahman, Senior Biotech Research Analyst, at the Maxim Group Virtual Healthcare Conference on June 22, 2023 at 1:00 PM ET.
This conference will be live on M-Vest. To attend, click here: Healthcare Virtual Conference | M-Vest.
About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.
| Contacts: | |
| Media Contact | Investor Contact |
| Ignacio Guerrero-Ros, Ph.D., or David Schull | Kevin Gardner |
| Russo Partners, LLC | LifeSci Advisors |
| [email protected] | [email protected] |
| [email protected] | 617-283-2856 |
| (858) 717-2310 |
Source: Clene Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
- Sui Price Prediction: Can SUI Hit $5 as Next Crypto To Explode AlphaPepe Builds Four Products Pre-Launch?
- Watershed Roofing Inc. Expands Roofing and Exterior Services Across British Columbia
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share